SCHEMBL6345175

SCHEMBL6345175

O=C(c1cc2c(S)c(C(=S)NCc3ccc(Cl)cc3)cnc2s1)N1CCOCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.44
KDM4E B2RXH2 3/20 0.43
MAPK1 P28482 2/20 0.43
LMNA P02545 2/20 0.43
RIPK1 Q13546 1/20 0.42
KCNH2 Q12809 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.38
ALDH1A1 P00352 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
HPGD P15428 2/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38
POLB P06746 1/20 0.38
TP53 P04637 1/20 0.37
GPR35 Q9HC97 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6660958 0.91 RXFP1 (0.51) RXFP1KDM4EMAPK1LMNARIPK1
SCHEMBL6707890 0.83 RXFP1 (0.52) RXFP1KDM4EMAPK1LMNARIPK1
SCHEMBL6339478 0.83 KCNH2 (0.51) RXFP1LMNAKCNH2
SCHEMBL6336443 0.82 KMT2A (0.46) RXFP1MAPK1LMNAKCNH2SMN1; SMN2
SCHEMBL6347826 0.78 RXFP1 (0.36) RXFP1MAPK1ALDH1A1GAAMAPT
SCHEMBL6340791 0.77 SMN1; SMN2 (0.35) MAPK1SMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL6339994 0.77 MAPT (0.37) MAPK1SMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL6664311 0.77 KCNH2 (0.62) RXFP1KCNH2ALDH1A1POLBTP53
SCHEMBL6343504 0.76 KCNH2 (0.53) KDM4EMAPK1LMNAKCNH2SMN1; SMN2
SCHEMBL6340795 0.75 RXFP1 (0.34) RXFP1HPGDCYP1A2MAPTCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924283-B2 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents PFIZER (US) 2005-08-02 US claimed
EP-1421088-A1 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2004-05-26 EP claimed
US-20030100536-A1 4-Thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2003-05-29 US claimed
WO-2003020730-A1 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-03-13 WO claimed
WO-2003020728-A1 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-03-13 WO claimed
US-6924283-B2 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents PFIZER (US) 2005-08-02 US disclosed
EP-1421088-A1 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2004-05-26 EP disclosed
US-20030100536-A1 4-Thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2003-05-29 US disclosed
WO-2003020730-A1 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100536-A1 4-Thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents TPMT, TK1, TYMP RXFP1 1245/4885KDM4E 492/4885MAPK1 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.